Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on May 5, 2022, at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The company specializes in developing therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes two first-in-class therapies currently in Phase 3 trials, with all five rare disease programs having received FDA breakthrough therapy designation. The webcast will be available for replay for at least 90 days.

Positive

• Two first-in-class therapies in Phase 3 targeting viral replication.
• All five rare disease programs granted FDA breakthrough therapy designation.

Negative

• None.

-  Live Conference Call and Webcast at 4:30 PM ET  -

PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 2392544. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.  All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-first-quarter-2022-financial-results-and-business-update-on-thursday-may-5-301530543.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What financial results will Eiger BioPharmaceuticals report on May 5, 2022?

Eiger BioPharmaceuticals will report its first quarter 2022 financial results during the conference call on May 5, 2022.

Where can I listen to the Eiger BioPharmaceuticals conference call?

The Eiger BioPharmaceuticals conference call can be accessed via their website at www.eigerbio.com.

What is Eiger BioPharmaceuticals focused on?

Eiger BioPharmaceuticals focuses on developing therapies for hepatitis delta virus (HDV) and other serious rare diseases.

What designations have Eiger's rare disease programs received?

All five of Eiger's rare disease programs have been granted FDA breakthrough therapy designation.